Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

These amendments introduce no new matter, and support for the amendment is replete throughout the specification and claims as originally filed. These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter or agreement with any objection or rejection of record.

Add claims 31-33 as shown below.

Listing of Claims:

Claims 1-19 (Canceled)

20. (Previously Presented) A method of treatment for diabetes, the method comprising administering to a subject in need thereof, a composition comprising P- and A-type inositolphosphoglycans, a P-type inositolphosphoglycan (IPG), or an antagonist of an A-type IPG.

21. (Previously Presented) The method of claim 20, wherein the composition has a ratio of P-type IPG to A-type IPG of from about 4:1 to about 6:1.

22. (Previously Presented) The method of claim 21, wherein the ratio is about 6:1 for a male subject or about 4:1 for a female subject.

23. (Previously Presented) A method of treatment for obese type II diabetes, the method comprising administering to a subject in need thereof, a composition comprising a P-type IPG and/or an A-type IPG antagonist.

24. (Previously Presented) The method of claim 23, wherein the A-type IPG antagonist is a monoclonal antibody capable of specifically binding an A-type IPG.

25. (Previously Presented) A method of treatment for IDDM or lean type II diabetes (NIDDM), the method comprising administering to a subject in need thereof, a composition comprising a mixture of a P-type IPG and an A-type IPG.

26. (Previously Presented) The method of claim 25, wherein the mixture comprises a ratio of P-type IPG to A-type IPG of about 6:1 for a male subject or about 4:1 for a female subject.

27. (Previously Presented) A pharmaceutical composition comprising a P-type IPG and/or an A-type IPG antagonist and a pharmaceutically acceptable carrier.

28. (Previously Presented) The pharmaceutical composition of claim 27, wherein the A-type IPG antagonist is a monoclonal antibody capable of specifically binding an A-type IPG.

29. (Previously Presented) A pharmaceutical composition comprising a mixture of a P-type IPG and an A-type IPG and a pharmaceutically acceptable carrier.

30. (Previously Presented) The composition of claim 29, wherein the mixture comprises a ratio of P-type IPG to A-type IPG of from about 4:1 to about 6:1.

31. (New) The method of claim 20, wherein the composition comprises a P-type IPG and an A-type IPG antagonist.

32. (New) The method of claim 23, wherein the composition comprises a P-type IPG and an A-type IPG antagonist.

33. (New) The composition of claim 27, wherein the composition comprises a P-type IPG and an A-type IPG antagonist.